Swiss National Bank Purchases 36,000 Shares of Eli Lilly and Company (LLY)
Swiss National Bank raised its position in Eli Lilly and Company (NYSE:LLY) by 0.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,157,443 shares of the company’s stock after acquiring an additional 36,000 shares during the period. Swiss National Bank owned about 377,575.22% of Eli Lilly and worth $355,628,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of LLY. Jaffetilchin Investment Partners LLC grew its stake in shares of Eli Lilly and by 119.6% in the 3rd quarter. Jaffetilchin Investment Partners LLC now owns 10,628 shares of the company’s stock valued at $909,000 after purchasing an additional 5,789 shares during the period. Maple Capital Management Inc. grew its stake in shares of Eli Lilly and by 2.4% in the 3rd quarter. Maple Capital Management Inc. now owns 96,166 shares of the company’s stock valued at $8,226,000 after purchasing an additional 2,270 shares during the period. Jacobi Capital Management LLC grew its stake in shares of Eli Lilly and by 65.7% in the 3rd quarter. Jacobi Capital Management LLC now owns 1,718 shares of the company’s stock valued at $150,000 after purchasing an additional 681 shares during the period. Blackhill Capital Inc. grew its stake in shares of Eli Lilly and by 0.6% in the 3rd quarter. Blackhill Capital Inc. now owns 154,915 shares of the company’s stock valued at $13,251,000 after purchasing an additional 1,000 shares during the period. Finally, Alethea Capital Management LLC bought a new stake in shares of Eli Lilly and in the 3rd quarter valued at approximately $808,000. 76.42% of the stock is owned by hedge funds and other institutional investors.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of the company’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $85.14, for a total value of $16,602,300.00. Following the transaction, the insider now directly owns 123,513,247 shares in the company, valued at approximately $10,515,917,849.58. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 651,088 shares of company stock worth $56,439,586. Company insiders own 0.20% of the company’s stock.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the prior year, the business earned $0.88 EPS. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. analysts anticipate that Eli Lilly and Company will post 4.22 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a yield of 2.60%. Eli Lilly and’s dividend payout ratio is currently 98.58%.
LLY has been the topic of several analyst reports. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a research note on Thursday, September 28th. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and set a $105.00 price target on shares of Eli Lilly and in a research report on Friday, October 13th. Jefferies Group restated a “buy” rating and set a $89.00 price target (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, Goldman Sachs Group restated a “buy” rating and set a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company’s stock. Eli Lilly and presently has an average rating of “Hold” and an average target price of $90.25.
COPYRIGHT VIOLATION WARNING: “Swiss National Bank Purchases 36,000 Shares of Eli Lilly and Company (LLY)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/12/16/swiss-national-bank-purchases-36000-shares-of-eli-lilly-and-company-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Stock Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related stocks with our FREE daily email newsletter.